- Sales decline primarily due to December 2018 recall of the PLX lumbar spine implant and termination of advisory agreement with a company that provided services to some Xtant customers
- Continuing to cut costs by streamlining manufacturing operations and the sales channel
- Hired additional sales personnel during the first half to bolster revenue stream
Performance by Segment
ORTHOWORLD estimates segment sales and growth on an as-reported basis, as follows ($MM):
2Q19 | 2Q18 | $ Chg | % Chg | |
Spine | $5.2 | $6.7 | -$1.6 | -23.0% |
Orthobiologics | $10.1 | $12.0 | -$1.9 | -16.0% |
Total | $15.3 | $18.7 | -$3.5 | -18.5% |
1H19 | 1H18 | $ Chg | % Chg | |
Spine | $10.9 | $13.2 | -$2.3 | -17.7% |
Orthobiologics | $21.1 | $23.5 | -$2.4 | -10.1% |
Total | $32.0 | $36.7 | -$4.7 | -12.9% |
Sales by Geographic Region
ORTHOWORLD estimates geographic sales and growth as follows ($MM):
2Q19 | 2Q18 | $ Chg | % Chg | |
US | $14.6 | $17.3 | -$2.7 | -15.8% |
Ex-US | $0.7 | $1.4 | -$0.7 | -51.8% |
Total | $15.3 | $18.7 | -$3.5 | -18.5% |
Net Earnings Data
Net earnings, inclusive of all revenue, are as follows.
Amt | % of Sales | |
Sales | $15.3 | |
Cost of Sales | -$5.4 | 35.1% |
General and Admin | -$4.0 | 26.5% |
Sales and Marketing | -$6.1 | 39.8% |
R & D | -$0.2 | 1.4% |
Other | -$1.5 | 9.8% |
Net Earnings | -$1.9 | -12.6% |
Sources: Xtant; ORTHOWORLD estimates.
Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.
Sales decline primarily due to December 2018 recall of the PLX lumbar spine implant and termination of advisory agreement with a company that provided services to some Xtant customers
Continuing to cut costs by streamlining manufacturing operations and the sales channel
Hired additional sales personnel during the first half...
- Sales decline primarily due to December 2018 recall of the PLX lumbar spine implant and termination of advisory agreement with a company that provided services to some Xtant customers
- Continuing to cut costs by streamlining manufacturing operations and the sales channel
- Hired additional sales personnel during the first half to bolster revenue stream
Performance by Segment
ORTHOWORLD estimates segment sales and growth on an as-reported basis, as follows ($MM):
2Q19 | 2Q18 | $ Chg | % Chg | |
Spine | $5.2 | $6.7 | -$1.6 | -23.0% |
Orthobiologics | $10.1 | $12.0 | -$1.9 | -16.0% |
Total | $15.3 | $18.7 | -$3.5 | -18.5% |
1H19 | 1H18 | $ Chg | % Chg | |
Spine | $10.9 | $13.2 | -$2.3 | -17.7% |
Orthobiologics | $21.1 | $23.5 | -$2.4 | -10.1% |
Total | $32.0 | $36.7 | -$4.7 | -12.9% |
Sales by Geographic Region
ORTHOWORLD estimates geographic sales and growth as follows ($MM):
2Q19 | 2Q18 | $ Chg | % Chg | |
US | $14.6 | $17.3 | -$2.7 | -15.8% |
Ex-US | $0.7 | $1.4 | -$0.7 | -51.8% |
Total | $15.3 | $18.7 | -$3.5 | -18.5% |
Net Earnings Data
Net earnings, inclusive of all revenue, are as follows.
Amt | % of Sales | |
Sales | $15.3 | |
Cost of Sales | -$5.4 | 35.1% |
General and Admin | -$4.0 | 26.5% |
Sales and Marketing | -$6.1 | 39.8% |
R & D | -$0.2 | 1.4% |
Other | -$1.5 | 9.8% |
Net Earnings | -$1.9 | -12.6% |
Sources: Xtant; ORTHOWORLD estimates.
Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.